INDIANAPOLIS (AP) — Eli Lilly & Co. said Monday the Food and Drug Administration approved the bipolar depression drug Symbyax as a therapy for treatment-resistant depression. The new indication applies to adult patients who have not responded to two separate rounds of therapy with different antidepressants. The FDA also approved the combined use of Zyprexa and fluoxetine, or Prozac, as a treatment for depression and treatment-resistant depression. Zyprexa is already approved for schizophrenia and bipolar disorder.
Related Articles Read More >

Pfizer’s revenue soared in the pandemic, but its stock valuation slipped relative to industry peers since 2000

FTC approves Amgen-Horizon merger

An interactive look at the drugs accounting for a fifth of Medicare’s spending
